A detailed history of Bill Few Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Bill Few Associates, Inc. holds 34,334 shares of ABBV stock, worth $5.85 Million. This represents 2.43% of its overall portfolio holdings.

Number of Shares
34,334
Previous 34,291 0.13%
Holding current value
$5.85 Million
Previous $5.88 Million 15.29%
% of portfolio
2.43%
Previous 2.28%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$163.84 - $199.33 $7,045 - $8,571
43 Added 0.13%
34,334 $6.78 Million
Q2 2024

Jul 16, 2024

SELL
$154.79 - $180.76 $60,368 - $70,496
-390 Reduced 1.12%
34,291 $5.88 Million
Q1 2024

Apr 18, 2024

BUY
$159.82 - $182.1 $89,179 - $101,611
558 Added 1.64%
34,681 $6.32 Million
Q4 2023

Jan 16, 2024

SELL
$137.6 - $154.97 $54,489 - $61,368
-396 Reduced 1.15%
34,123 $5.29 Million
Q3 2023

Oct 20, 2023

BUY
$133.59 - $154.65 $63,321 - $73,304
474 Added 1.39%
34,519 $5.15 Million
Q2 2023

Jul 18, 2023

SELL
$132.51 - $164.9 $64,399 - $80,141
-486 Reduced 1.41%
34,045 $4.59 Million
Q1 2023

Apr 17, 2023

BUY
$144.61 - $166.54 $67,243 - $77,441
465 Added 1.36%
34,531 $5.5 Million
Q4 2022

Jan 24, 2023

SELL
$138.31 - $165.87 $35,822 - $42,960
-259 Reduced 0.75%
34,066 $0
Q3 2022

Oct 13, 2022

SELL
$134.21 - $153.93 $312,306 - $358,195
-2,327 Reduced 6.35%
34,325 $4.61 Million
Q2 2022

Jul 26, 2022

SELL
$137.62 - $174.96 $100,875 - $128,245
-733 Reduced 1.96%
36,652 $5.61 Million
Q1 2022

Apr 27, 2022

BUY
$131.98 - $163.75 $16,497 - $20,468
125 Added 0.34%
37,385 $6.06 Million
Q4 2021

Mar 04, 2022

BUY
$107.43 - $135.93 $4 Million - $5.06 Million
37,260 New
37,260 $5.05 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bill Few Associates, Inc. Portfolio

Follow Bill Few Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bill Few Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bill Few Associates, Inc. with notifications on news.